Niclosamide (NIC) has emerged as a promising human endometrial cancer treatment by inducing Bax colocalization with lysosome and inhibiting Cathepsin B maturation from pro-cathepsin B, which induces lysosomal membrane permeability and releases hydrolase enzymes from the lysosome to cytosol, ultimately leading to cell death (122). The gene discussed is CTSB; the disease is endometrial cancer.